MilliporeSigma, a Life Science and High Technology company, has extended its ongoing collaboration with Baylor College of Medicine, it was reported on Wednesday.

The collaboration has been extended to advance a manufacturing platform to fight Covid-19, accelerating the transition to Phase one clinical trials.

The partnership is intended to improve the manufacturing platform for the CoV RBD219-N1 vaccine candidate, which was originally developed to target SARS in 2011-2016. The companies will also develop a new manufacturing platform for a second Covid-19 vaccine candidate to reduce the time to enter into Phase one clinical trials. The aim of the partnership is to develop a suitable manufacturing process and steps that lead to a scale-up approach suitable for pilot and later industrial production.